Promoter polymorphisms of miR-34b/c are associated with risk of gastric cancer in a Chinese population

Tumor Biology

Volumn 35, Issue 12, 2014, Pages 12545-12554

  Yang, Chao ^a   Ma, Xiang ^a   Liu, Dongxiao ^b   Wang, Younan ^a   Tang, Ran ^a   Zhu, Yi ^c   Xu, Zekuan ^a   Yang, Li ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b Nanjing Second Hospital   (China)

^c Jiangsu Province Academy of Clinical Medicine   (China)

Author keywords

Gastric cancer; Genotype; miR 34b c; Polymorphism; TP53

Indexed keywords

ARGININE; MICRORNA; MICRORNA 34B; MICRORNA 34C; PROLINE; PROTEIN P53; UNCLASSIFIED DRUG; MIRN34 MICRORNA, HUMAN;

ALLELE; ARTICLE; CANCER PATIENT; CANCER RISK; CASE CONTROL STUDY; CHINESE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; STOMACH CANCER; WILD TYPE; AGED; CANCER GRADING; CANCER STAGING; CHINA; GENETIC PREDISPOSITION; GENETICS; METASTASIS; MIDDLE AGED; RISK; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH TUMOR; TUMOR SUPPRESSOR GENE;

AGED; ALLELES; CASE-CONTROL STUDIES; CHINA; FEMALE; GENES, P53; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; RISK FACTORS; STOMACH NEOPLASMS;

EID: 84925286924     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2574-9     Document Type: Article

References (36)

1. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol. 2006;12(3):354–62.
2. Ushijima T, Sasako M. Focus on gastric cancer. Cancer Cell. 2004;5(2):121–5.
3. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process—first American Cancer Society award lecture on cancer epidemiology and prevention. Cancer Res. 1992;52(24):6735–40.
4. Wu MS, Chen CJ, Lin JT. Host-environment interactions: their impact on progression from gastric inflammation to carcinogenesis and on development of new approaches to prevent and treat gastric cancer. Cancer Epidemiol Biomarkers Prev. 2005;14(8):1878–82. doi:10.1158/1055-9965.EPI-04-0792.
5. Zhu H, Yang L, Zhou B, Yu R, Tang N, Wang B. Myeloperoxidase G-463A polymorphism and the risk of gastric cancer: a case–control study. Carcinogenesis. 2006;27(12):2491–6. doi:10.1093/carcin/bgl121.
6. Gu H, Yang L, Tang N, Zhou B, Zhu H, Sun Q, et al. Association of endothelin-converting enzyme-1b C-338A polymorphism with gastric cancer risk: a case–control study. Eur J Cancer. 2008;44(9):1253–8. doi:10.1016/j.ejca.2007.09.013.
7. Yang L, Gu HJ, Zhu HJ, Sun QM, Cong RH, Zhou B, et al. Tissue inhibitor of metalloproteinase-2 G-418C polymorphism is associated with an increased risk of gastric cancer in a Chinese population. Eur J Surg Oncol. 2008;34(6):636–41. doi:10.1016/j.ejso.2007.09.003.
8. Rozan LM, El-Deiry WS. p53 downstream target genes and tumor suppression: a classical view in evolution. Cell Death Differ. 2007;14(1):3–9. doi:10.1038/sj.cdd.4402058.
9. Lane DP. Cancer. p53, guardian of the genome. Nature. 1992;358(6381):15–6.
10. Naccarati A, Polakova V, Pardini B, Vodickova L, Hemminki K, Kumar R, et al. Mutations and polymorphisms in TP53 gene—an overview on the role in colorectal cancer. Mutagenesis. 2012;27(2):211–8. doi:10.1093/mutage/ger067.
11. Ara S, Lee PS, Hansen MF, Saya H. Codon 72 polymorphism of the TP53 gene. Nucleic Acids Res. 1990;18(16):4961.
12. Hadhri-Guiga B, Toumi N, Khabir A, Sellami-Boudawara T, Ghorbel A, Daoud J, et al. Proline homozygosity in codon 72 of TP53 is a factor of susceptibility to nasopharyngeal carcinoma in Tunisia. Cancer Genet Cytogenet. 2007;178(2):89–93. doi:10.1016/j.cancergencyto.2007.05.013.
13. Jiang P, Liu J, Zeng X, Li W, Tang J. Association of TP53 codon 72 polymorphism with cervical cancer risk in Chinese women. Cancer Genet Cytogenet. 2010;197(2):174–8. doi:10.1016/j.cancergencyto.2009.11.011.
14. Gao LB, Li LJ, Pan XM, Li ZH, Liang WB, Bai P, et al. A genetic variant in the promoter region of miR-34b/c is associated with a reduced risk of colorectal cancer. Biol Chem. 2013;394(3):415–20. doi:10.1515/hsz-2012-0297/j/bchm.2013.394.issue-3/hsz-2012-0297/hsz-2012-0297.xml.
15. Denisov EV, Cherdyntseva NV, Litvyakov NV, Slonimskaya EM, Malinovskaya EA, Voevoda MI, et al. TP53 mutations and Arg72Pro polymorphism in breast cancers. Cancer Genet Cytogenet. 2009;192(2):93–5. doi:10.1016/j.cancergencyto.2009.03.014.
16. Fernandez-Rubio A, Lopez-Cima MF, Gonzalez-Arriaga P, Garcia-Castro L, Pascual T, Marron MG, et al. The TP53 Arg72Pro polymorphism and lung cancer risk in a population of Northern Spain. Lung Cancer. 2008;61(3):309–16. doi:10.1016/j.lungcan.2008.01.017.
17. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell. 2007;26(5):745–52. doi:10.1016/j.molcel.2007.05.010.
18. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, et al. A microRNA component of the p53 tumour suppressor network. Nature. 2007;447(7148):1130–4. doi:10.1038/nature05939.
19. Xu Y, Liu L, Liu J, Zhang Y, Zhu J, Chen J, et al. A potentially functional polymorphism in the promoter region of miR-34b/c is associated with an increased risk for primary hepatocellular carcinoma. Int J Cancer. 2011;128(2):412–7. doi:10.1002/ijc.25342.
20. Bossard P, Zaret KS. GATA transcription factors as potentiators of gut endoderm differentiation. Development. 1998;125(24):4909–17.
21. Chou J, Provot S, Werb Z. GATA3 in development and cancer differentiation: cells GATA have it! J Cell Physiol. 2010;222(1):42–9. doi:10.1002/jcp.21943.
22. Son MS, Jang MJ, Jeon YJ, Kim WH, Kwon CI, Ko KH, et al. Promoter polymorphisms of pri-miR-34b/c are associated with hepatocellular carcinoma. Gene. 2013;524(2):156–60. doi:10.1016/j.gene.2013.04.042.
23. Zhang S, Qian J, Cao Q, Li P, Wang M, Wang J, et al. A potentially functional polymorphism in the promoter region of miR-34b/c is associated with renal cell cancer risk in a Chinese population. Mutagenesis. 2014;29(2):149–54. doi:10.1093/mutage/geu001.
24. Li L, Sima X, Bai P, Zhang L, Sun H, Liang W, et al. Interactions of miR-34b/c and TP53 polymorphisms on the risk of intracranial aneurysm. Clin Dev Immunol. 2012;2012:567586. doi:10.1155/2012/567586.
25. Li L, Wu J, Sima X, Bai P, Deng W, Deng X, et al. Interactions of miR-34b/c and TP-53 polymorphisms on the risk of nasopharyngeal carcinoma. Tumour Biol. 2013;34(3):1919–23. doi:10.1007/s13277-013-0736-9.
26. Wei YG, Liu F, Li B, Chen X, Ma Y, Yan LN, et al. Interleukin-10 gene polymorphisms and hepatocellular carcinoma susceptibility: a meta-analysis. World J Gastroenterol. 2011;17(34):3941–7. doi:10.3748/wjg.v17.i34.3941.
27. Zhang YM, Zhou XC, Xu Z, Tang CJ. Meta-analysis of epidemiological studies of association of two polymorphisms in the interleukin-10 gene promoter and colorectal cancer risk. Genet Mol Res. 2012;11(3):3389–97. doi:10.4238/2012.September.25.7.
28. Christoffersen NR, Shalgi R, Frankel LB, Leucci E, Lees M, Klausen M, et al. p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC. Cell Death Differ. 2010;17(2):236–45. doi:10.1038/cdd.2009.109.
29. Hermeking H. The miR-34 family in cancer and apoptosis. Cell Death Differ. 2010;17(2):193–9. doi:10.1038/cdd.2009.56.
30. Kim NH, Kim HS, Kim NG, Lee I, Choi HS, Li XY, et al. p53 and microRNA-34 are suppressors of canonical Wnt signaling. Sci Signal. 2011;4(197):ra71. doi:10.1126/scisignal.2001744.
31. Tazawa H, Tsuchiya N, Izumiya M, Nakagama H. Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc Natl Acad Sci U S A. 2007;104(39):15472–7. doi:10.1073/pnas.0707351104.
32. Suzuki R, Yamamoto E, Nojima M, Maruyama R, Yamano HO, Yoshikawa K, et al. Aberrant methylation of microRNA-34b/c is a predictive marker of metachronous gastric cancer risk. J Gastroenterol. 2013. doi:10.1007/s00535-013-0861-7.
33. Toyota M, Suzuki H, Sasaki Y, Maruyama R, Imai K, Shinomura Y, et al. Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res. 2008;68(11):4123–32. doi:10.1158/0008-5472.CAN-08-0325.
34. Song HR, Kweon SS, Kim HN, Piao JM, Yun WJ, Choi JS, et al. p53 codon 72 polymorphism in patients with gastric and colorectal cancer in a Korean population. Gastric Cancer. 2011;14(3):242–8. doi:10.1007/s10120-011-0034-4.
35. Shen H, Solari A, Wang X, Zhang Z, Xu Y, Wang L, et al. P53 codon 72 polymorphism and risk of gastric cancer in a Chinese population. Oncol Rep. 2004;11(5):1115–20.
36. Sul J, Yu GP, Lu QY, Lu ML, Setiawan VW, Wang MR, et al. P53 codon 72 polymorphisms: a case–control study of gastric cancer and potential interactions. Cancer Lett. 2006;238(2):210–23. doi:10.1016/j.canlet.2005.07.004.